STAT3 and neoplasm: M2 TAMs secrete large amounts of IL‐10 in the TME, which stimulate JAK/STAT signaling in the tumor, lowers paclitaxel's effectiveness via the IL‐10/STAT3/Bcl‐2 cascade, and enhances paclitaxel resistance [48].